{"id":"ulimorelin-invtravenously-iv","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Vomiting"},{"rate":"5-10%","effect":"Abdominal pain"}]},"_chembl":{"chemblId":"CHEMBL1963249","moleculeType":"Small molecule","molecularWeight":"538.66"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Ulimorelin works by activating the ghrelin receptor, which is involved in regulating gastric motility and emptying. This leads to an increase in gastric emptying, which can help alleviate symptoms of gastroparesis.","oneSentence":"Ulimorelin is a ghrelin receptor agonist that stimulates gastric emptying.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:52:13.415Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Symptomatic gastroesophageal reflux disease (GERD) in patients with type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT01296620","phase":"PHASE3","title":"Ulimorelin Study of Efficacy and Safety (ULISES 008)","status":"COMPLETED","sponsor":"Tranzyme, Inc.","startDate":"2011-02","conditions":"Gastrointestinal Dysmotility","enrollment":330}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Ulimorelin Invtravenously (IV)","genericName":"Ulimorelin Invtravenously (IV)","companyName":"Tranzyme, Inc.","companyId":"tranzyme-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ulimorelin is a small molecule administered intravenously (IV) for the treatment of gastrointestinal dysmotility. It is a synthetic compound that has been studied in clinical trials, including the ULISES 008 study, to evaluate its efficacy and safety.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}